Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Zogenix, Inc. (NASDAQ: ZGNX).

Full DD Report for ZGNX

You must become a subscriber to view this report.


Recent News from (NASDAQ: ZGNX)

New Research: Key Drivers of Growth for Ashland Global, Intellia Therapeutics, Thor Industries, Zogenix, BWX Technologies, and Heidrick & Struggles International - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ashland Global Holdings Inc. (NYSE:ASH), Intellia Therapeutics, Inc. (...
Source: GlobeNewswire
Date: December, 17 2018 07:25
Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of FINTEPLA® (ZX008) in Dravet Syndrome
Positive Data from Second Pivotal Phase 3 Trial (Study 1504) Consistent with Results of First Phase 3 Trial in Showing Highly Significant Convulsive Seizure Reduction for FINTEPLA versus Placebo Clinically Meaningful Reduction in Convulsive Seizure Frequency for FINTEPLA Maintained Ov...
Source: GlobeNewswire
Date: December, 03 2018 09:00
Zogenix Presents Positive Findings on the Impact of Treatment with FINTEPLA® (ZX008) on Everyday Executive Function in Patients with Dravet Syndrome
Data Presented During Late-Breaker Session at 72 nd   American Epilepsy Society Annual Meeting Additional New Analyses Underscore Psychosocial Burden on Family EMERYVILLE, Calif., Dec. 02, 2018 (GLOBE NEWSWIRE) --  Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company de...
Source: GlobeNewswire
Date: December, 02 2018 09:00
Notable earnings after Thursday's close
AGO , AL , ALTR , AMBR , AMC , AMPH , AQN , ARRS , ASRT , ATVI , BOJA , BPI , BRS , BW , CBPX , COLD , COLL , CTL , CYRX , DBX , DIS , DOX , ECOM , EGAN , EPAY , ERI , FGEN , FOE , FSCT , FSM , FTCH , GMED , HDP , HTZ , ICUI , JAG , JJSF , LGF.A , LOPE...
Source: SeekingAlpha
Date: November, 07 2018 17:35
Zogenix to Present at Stifel 2018 Healthcare Conference
EMERYVILLE, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive...
Source: GlobeNewswire
Date: November, 07 2018 08:00
Zogenix to Release Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 8
EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter ended September...
Source: GlobeNewswire
Date: November, 01 2018 08:00
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to three new non-executive employees. The ...
Source: GlobeNewswire
Date: October, 01 2018 17:07
Zogenix to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
EMERYVILLE, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executiv...
Source: GlobeNewswire
Date: September, 25 2018 08:00
Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication
News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp...
Source: SeekingAlpha
Date: September, 07 2018 16:31
Zogenix's ZX008 shows positive effect in mid-stage study in rare childhood epilepsy; shares up 5% premarket
Zogenix (NASDAQ: ZGNX ) is up  5%  premarket on light volume on the heels of its announcement of positive results from a Phase 2 clinical trial evaluating ZX008 in patients with Lennox-Gastaut syndrome (LGS), a rare and severe type of childhood epilepsy. The data were just publis...
Source: SeekingAlpha
Date: September, 04 2018 08:52

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0846.8547.2548.6546.45951,889
2018-05-1739.7039.9540.7539.601705,232
2017-03-108.809.759.758.50320,699
2017-03-099.409.559.759.35248,683
2017-03-089.459.409.7259.35139,564

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1774,430147,10650.5962Short
2018-12-1474,859159,70046.8748Short
2018-12-1391,538138,78165.9586Short
2018-12-1216,54624,24468.2478Short
2018-12-1190,367247,53136.5073Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ZGNX.


About Zogenix, Inc. (NASDAQ: ZGNX)

Logo for Zogenix, Inc. (NASDAQ: ZGNX)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $741,897,112 - 05/11/2018
    • Issue and Outstanding: 19,170,468 - 07/01/2015

     


    Recent Filings from (NASDAQ: ZGNX)

    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 09 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 09 2018
    Securities offered to employees under employee benefit plans
    Filing Type: S-8Filing Source: edgar
    Filing Date: May, 09 2018
    Official notification to shareholders of matters to be brought to a vote (Proxy)
    Filing Type: DEF 14AFiling Source: edgar
    Filing Date: April, 13 2018
    Additional proxy soliciting materials - definitive
    Filing Type: DEFA14AFiling Source: edgar
    Filing Date: April, 13 2018
    Filing Type: CT ORDERFiling Source: edgar
    Filing Date: March, 06 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: March, 06 2018
    Annual report with a comprehensive overview of the company
    Filing Type: 10-KFiling Source: edgar
    Filing Date: March, 06 2018
    Amendment to the SC 13G filing
    Filing Type: SC 13G/AFiling Source: edgar
    Filing Date: February, 14 2018
    Amendment to the SC 13G filing
    Filing Type: SC 13G/AFiling Source: edgar
    Filing Date: February, 14 2018

     

     


    Daily Technical Chart for (NASDAQ: ZGNX)

    Daily Technical Chart for (NASDAQ: ZGNX)


    Stay tuned for daily updates and more on (NASDAQ: ZGNX)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: ZGNX)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ZGNX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ZGNX and does not buy, sell, or trade any shares of ZGNX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/